- Home
- TLPH vs RDHL Comparison
TLPH vs RDHL Comparison
Compare TLPH & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- RDHL
- Stock Information
- Founded
- TLPH 2005
- RDHL 2009
- Country
- TLPH United States
- RDHL Israel
- Employees
- TLPH N/A
- RDHL N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- TLPH Health Care
- RDHL Health Care
- Exchange
- TLPH Nasdaq
- RDHL Nasdaq
- Market Cap
- TLPH 10.6M
- RDHL 4.3M
- IPO Year
- TLPH 2011
- RDHL N/A
- Fundamental
- Price
- TLPH $0.52
- RDHL $2.15
- Analyst Decision
- TLPH Strong Buy
- RDHL
- Analyst Count
- TLPH 1
- RDHL 0
- Target Price
- TLPH $6.00
- RDHL N/A
- AVG Volume (30 Days)
- TLPH 49.7K
- RDHL 18.4K
- Earning Date
- TLPH 08-13-2025
- RDHL 08-28-2025
- Dividend Yield
- TLPH N/A
- RDHL N/A
- EPS Growth
- TLPH N/A
- RDHL N/A
- EPS
- TLPH N/A
- RDHL N/A
- Revenue
- TLPH $27,000.00
- RDHL $8,042,999.00
- Revenue This Year
- TLPH N/A
- RDHL $381.91
- Revenue Next Year
- TLPH $14,533.26
- RDHL N/A
- P/E Ratio
- TLPH N/A
- RDHL N/A
- Revenue Growth
- TLPH N/A
- RDHL 23.17
- 52 Week Low
- TLPH $0.43
- RDHL $1.71
- 52 Week High
- TLPH $1.19
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- TLPH 61.24
- RDHL 64.10
- Support Level
- TLPH $0.44
- RDHL $2.00
- Resistance Level
- TLPH $0.52
- RDHL $2.08
- Average True Range (ATR)
- TLPH 0.03
- RDHL 0.09
- MACD
- TLPH 0.01
- RDHL 0.03
- Stochastic Oscillator
- TLPH 93.89
- RDHL 100.00
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.